New Delhi, April 11 -- Tata Consultancy Services (TCS), India's leading IT services provider, released its Q4 FY25 earnings on Thursday, April 10. The company reported a 1.6% drop in consolidated net profit, amounting to Rs.12,224 crore. Despite the dip in profit, TCS saw its revenue rise on a year-on-year basis, reaching Rs.64,479 crore compared to Rs.61,237 crore in the corresponding quarter of the previous fiscal year.

CuraTeQ Biologics, a subsidiary of the company, has successfully concluded the Phase 1 study assessing the pharmacokinetics (PK) and pharmacodynamics (PD) of its denosumab biosimilar, BP16. Denosumab functions by selectively inhibiting the RANK ligand (RANKL), a key protein involved in the regulation of osteoclasts-cell...